Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Inclusion Criteria: * Patients with histologically confirmed PTCL. Biopsy proof of disease at initial diagnosis is mandatory. A biopsy at relapse is preferred but not mandatory. * Patients must have received one or two previous regimens of therapy for their disease (salvage chemotherapy plus autologous stem cell transplantation is considered to be one regimen). * Clinically and / or radiologically measurable disease (1 site bidimensionally measurable). Measurements / evaluations must be done within 28 days prior to registration. * Age 18 to 75 years. * ECOG performance status 0, 1 or 2. * Life expectancy of ≥ 90 days (3 months). * Laboratory Requirements: (must be done within 7 days of registration) Hematology: * Granulocytes (AGC) ≥ 1.0 x 10\^9/L * Platelets ≥ 75 x 10\^9/L (≥ 50 if bone marrow involvement by lymphoma) Biochemistry: * AST and ALT ≤ 2.5x ULN (≤ 5x ULN if hepatic involvement of disease) * Serum total bilirubin ≤ 1.5x ULN (≤ 3x ULN if hepatic involvement of disease, or ≤5x ULN if Gilberts Disease) * Serum Potassium ≥ 3.8 mmol/L\* * Serum Magnesium ≥ 0.85 mmol/L\* \* NB: Patients with potassium and magnesium levels below these values are eligible if supplementation has corrected these deficits. This supplementation should continue throughout the course of the study. * Calculated creatinine clearance (Cockcroft-Gault formula) of ≥ 50 mL /min. * Women must be post-menopausal, surgically sterile or use reliable forms of contraception while on study and for…